Results 91 to 100 of about 1,342,058 (331)

The Political Economy of Conservation at Mount Elgon, Uganda: Between Local Deprivation, Regional Sustainability, and Global Public Goods

, 2016
This paper presents a case study from Mount Elgon National Park, Uganda, examining and deepening an understanding of direct incomes and costs of conservation for local people close to protected areas.
P. Vedeld, C. Cavanagh, J. Pétursson, C. Nakakaawa, Ricarda Moll, E. Sjaastad   +5 more
semanticscholar   +1 more source

Next‐generation proteomics improves lung cancer risk prediction

Molecular Oncology, EarlyView.
This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj, Clara Frick, Ben Schöttker, Bernd Holleczek, Hermann Brenner   +4 more
wiley   +1 more source

KÜRESEL KAMUSAL MALLAR VE FİNANSMANI GLOBAL PUBLIC GOODS AND FINANCING

Selçuk Üniversitesi Sosyal Bilimler Meslek Yüksekokulu Dergisi, 2014
Küresel kamusal mallar genelde önemsenmeyen ancak aynı derecede önemli bir kavramdır. Yaşamın devamı, iklim değişikliğinin, savaşların, hastalıkların engellenmesi, bütünleşmenin, serbest ticaretin insan haklarının gelişmesi için gerekli her türlü mal ve ...
Hasan Sencer Peker, İsa Altınışık
doaj  

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

Patenting the Sun? Possible Exclusion of SRM Technologies from Patenting and Risk Regulation

European Journal of Risk Regulation
In an interview with Jonas Salk, the inventor of the first polio vaccine, when asked whether he owned the patents for the vaccine, Salk replied with a rhetorical question: “Could you patent the sun?” Decades later, patents about the Sun indeed emerged as
Wenting Cheng
doaj   +1 more source

LINC01116, a hypoxia‐lncRNA marker of pathological lymphangiogenesis and poor prognosis in lung adenocarcinoma

Molecular Oncology, EarlyView.
The LINC01116 long noncoding RNA is induced by hypoxia and associated with poor prognosis and high recurrence rates in two cohorts of lung adenocarcinoma patients. Here, we demonstrate that besides its expression in cancer cells, LINC01116 is markedly expressed in lymphatic endothelial cells of the tumor stroma in which it participates in hypoxia ...
Marine Gautier‐Isola, Rafael Lopes Goncalves, Marin Truchi, Caroline Lacoux, Célia Scribe, Hugo Cadis, Laetitia Guardini, Sophie Bekisz, Marius Ilié, Paul Hofman, Georges Vassaux, Bernard Mari, Roger Rezzonico   +12 more
wiley   +1 more source

Contributing or Free-Riding? Voluntary Participation in a Public Good Economy [PDF]

We consider a (pure) public goods provision problem with voluntary participation in a quasi-linear economy. We propose a new hybrid solution concept, the free-riding-proof core (FRP-Core), which endogenously determines a contribution group, public good ...
Hideo Konishi, Taiji Furusawa
core   +3 more sources

Marketing in the Public Sector [PDF]

, 2010
{Excerpt} The public sector is the part of economic life, not in private ownership, that deals with the production, delivery, and allocation of basic public goods and services at global, regional, national, or local levels.
Serrat, Olivier
core   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

The public goods hypothesis for the evolution of life on Earth

Biology Direct, 2011
It is becoming increasingly difficult to reconcile the observed extent of horizontal gene transfers with the central metaphor of a great tree uniting all evolving entities on the planet. In this manuscript we describe the Public Goods Hypothesis and show
Bapteste Eric, Pisani Davide, McInerney James O, O'Connell Mary J   +3 more
doaj   +1 more source